These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2676565)

  • 1. Endothelin-3: selectivity as an anti-aggregatory peptide in vivo.
    Lidbury PS; Thiemermann C; Thomas GR; Vane JR
    Eur J Pharmacol; 1989 Jul; 166(2):335-8. PubMed ID: 2676565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelin-1 inhibits platelet aggregation in vivo: a study with 111indium-labelled platelets.
    Thiemermann C; May GR; Page CP; Vane JR
    Br J Pharmacol; 1990 Feb; 99(2):303-8. PubMed ID: 2183912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin-1 releases prostacyclin and inhibits ex vivo platelet aggregation in the anesthetized rabbit.
    Thiemermann C; Lidbury PS; Thomas GR; Vane JR
    J Cardiovasc Pharmacol; 1989; 13 Suppl 5():S138-41; discussion S142. PubMed ID: 2473289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endothelin ETB receptor agonist, IRL 1620, causes vasodilatation and inhibits ex vivo platelet aggregation in the anaesthetised rabbit.
    McMurdo L; Thiemermann C; Vane JR
    Eur J Pharmacol; 1994 Jun; 259(1):51-5. PubMed ID: 7957593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelins release tissue plasminogen activator and prostanoids.
    Lidbury PS; Thiemermann C; Korbut R; Vane JR
    Eur J Pharmacol; 1990 Sep; 186(2-3):205-12. PubMed ID: 2127021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mediation of endothelin-1-induced inhibition of platelet aggregation via the ETB receptor.
    McMurdo L; Lidbury PS; Thiemermann C; Vane JR
    Br J Pharmacol; 1993 Jun; 109(2):530-4. PubMed ID: 8358553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissociation of the anti-ischaemic effects of cloricromene from its anti-platelet activity.
    Lidbury PS; Cirillo R; Vane JR
    Br J Pharmacol; 1993 Sep; 110(1):275-80. PubMed ID: 8220889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostacyclin mediates antiaggregatory and hypotensive actions of endothelin in anaesthetized beagle dogs.
    Hermán F; Magyar K; Chabrier PE; Braquet P; Filep J
    Br J Pharmacol; 1989 Sep; 98(1):38-40. PubMed ID: 2508983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin inhibits ex vivo platelet aggregation in the rabbit.
    Thiemermann C; Lidbury P; Thomas R; Vane J
    Eur J Pharmacol; 1988 Dec; 158(1-2):181-2. PubMed ID: 3065092
    [No Abstract]   [Full Text] [Related]  

  • 11. [Inhibition of serotonin-induced platelet aggregation by endothelins].
    Takada A; Takada Y
    Nihon Rinsho; 1992 Feb; 50(2):315-8. PubMed ID: 1613985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial ischaemia induced by endothelin in the intact rabbit: angiographic analysis.
    Hirata K; Matsuda Y; Akita H; Yokoyama M; Fukuzaki H
    Cardiovasc Res; 1990 Nov; 24(11):879-83. PubMed ID: 2272065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ETB and B2 receptors in the ex vivo platelet inhibitory properties of endothelin and bradykinin in the mouse.
    Labonté J; Brochu I; Honoré JC; D'Orléans-Juste P
    Br J Pharmacol; 2001 Feb; 132(4):934-40. PubMed ID: 11181435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelins inhibit serotonin-induced platelet aggregation via a mechanism involving protein kinase C.
    Pietraszek MH; Takada Y; Takada A
    Eur J Pharmacol; 1992 Aug; 219(2):289-93. PubMed ID: 1425954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits.
    Roussa VD; Stathopoulou EM; Papamichael ND; Englezopoulos CV; Rousouli KI; Trypou P; Moussis V; Tellis CC; Katsouras CS; Tsikaris V; Tselepis AD; Michalis LK
    Platelets; 2011; 22(5):361-70. PubMed ID: 21158497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An investigation of the antiplatelet effects of succinobucol (AGI-1067).
    Houston SA; Ugusman A; Gnanadesikan S; Kennedy S
    Platelets; 2017 May; 28(3):295-300. PubMed ID: 27681689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacological properties of the peptide, endothelin.
    Eglen RM; Michel AD; Sharif NA; Swank SR; Whiting RL
    Br J Pharmacol; 1989 Aug; 97(4):1297-307. PubMed ID: 2551446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravascular big endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbit.
    D'Orléans-Juste P; Lidbury PS; Warner TD; Vane JR
    Biochem Pharmacol; 1990 May; 39(9):R21-2. PubMed ID: 2110457
    [No Abstract]   [Full Text] [Related]  

  • 19. The in vivo antiaggregatory action of endothelin-1 is not mediated through the endothelin ETA receptor.
    Hermán F; Yano M; Filep JG
    Eur J Pharmacol; 1993 May; 236(1):143-6. PubMed ID: 8319738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin endoperoxides, thromboxane A2 and adenosine diphosphate in collagen-induced aggregation of rabbit platelets.
    Lewis GP; Watts IS
    Br J Pharmacol; 1982 Apr; 75(4):623-31. PubMed ID: 6802211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.